Cramer: Apple Is Th...
Elan Corp PLC (ELN: NYSE)
$13.39 -0.57 | -4.08%
06/01/12 - 04:03 PM ET
TheStreet Ratings Grade for ELN
| Buy | Hold | Sell | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A+ | A | A- | B+ | B | B- | C+ | C | C- | D+ | D | D- | E+ | E | E- | F |
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions.
Analyst Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Stong Buy | 1 | 1 | 1 | 1 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2.00 | 2.00 | 2.00 | 2.00 |
Portfolios with ELN
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- ProGeorge Soros
- UserGFNN Stockdiagnostics 13
- ContributorBreakout Stocks Of The Week...
- UserGFNN Stockdiagnostics
- ContributorRelative Strength Trades fo...
- ContributorStocks At New 52-Week Highs...
- ProRobert Bruce
- ContributorTechnical Setups for the We...
- Contributor10 Health Care Stocks With ...
Latest ELN Headlines from TheStreet
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- A Health Care Fortnight for the Record Books 05.14.12 | 07:05 am
- On Nowruz, Reviewing Drug Stock Picks 03.26.12 | 07:03 am
- Elan's Alzheimer's-Fueled Run Means Investors Are Forgetting the Past 03.19.12 | 07:03 am
- The Case for Shorting Elan Into Upcoming Alzheimer's Trial Results 02.21.12 | 07:02 am
- Medivation Shrugs Off Alzheimer's Setback as Investors Eye New Prostate Cancer Data 01.17.12 | 09:01 am
- 7 Relative Strength Stocks for 2012 12.29.11 | 05:12 pm
- 7 Stocks Hitting New 52-Week Highs 12.21.11 | 01:12 pm
- Your Vote Counts: Who is the Worst Biotech CEO of 2011? 12.01.11 | 10:12 am
- Good Biotech Stocks for a Bear Market 08.09.11 | 08:08 am
Press Releases for ELN
- Elan To Present At Jefferies 2012 Global Healthcare Conference - Business Wire 05.28.12 | 08:05 am
- New Analysis Of Risk Stratification For TYSABRI® Published In New England Journal Of Medicine - Business Wire 05.17.12 | 03:05 pm
- Elan Reports First Quarter 2012 Financial Results - Business Wire 04.26.12 | 02:04 am
- Elan Announces Webcast Of First Quarter 2012 Financial Results - Business Wire 04.12.12 | 04:04 pm
- Elan Raises $381 Million In Sale Of 76% Of Alkermes Holding - Business Wire 03.13.12 | 12:03 pm
- Elan Chairman Provides Update On CEO Succession - Business Wire 03.01.12 | 02:03 am
- Elan Reports Fourth Quarter And Full-Year 2011 Financial Results - Business Wire 02.08.12 | 02:02 am
- Elan To Present At The Leerink Swann 2012 Global Healthcare Conference - Business Wire 02.01.12 | 04:02 pm
- ASCEND Study To Evaluate The Effectiveness Of TYSABRI® (natalizumab) As A Treatment For Secondary-Progressive Multiple Sclerosis - Business Wire 01.26.12 | 08:01 am
- FDA Updates TYSABRI® (natalizumab) Label To Include Anti-JC Virus Antibody Status As A PML Risk Factor - Business Wire 01.20.12 | 04:01 pm
Partner Headlines for ELN
- Healthcare Biz Recap: Express Scripts New Driver, Elan Pops - Wall St. Cheat Sheet 05.27.12 | 12:05 pm
- Billionaire Soros' Q1 High Conviction Buys In 2 Growth Stocks, Other Buys And Sells - Seeking Alpha 05.18.12 | 08:05 pm
- Revenues Climb at Acorda - Analyst Blog - Zacks 05.04.12 | 06:05 pm
- Elan Misses 1Q EPS, Revenues Rise - Analyst Blog - Zacks 05.01.12 | 09:05 am
- Elan Sells 76% Stake in Alkermes - Analyst Blog - Zacks 03.16.12 | 05:03 pm
- Tuesday's Bio Pharma Watch List - Seeking Alpha 02.28.12 | 08:02 am
- Zacks Sell List Highlights: Expedia, NII Holdings, Elan and Gentex - Press Releases - Zacks 02.17.12 | 09:02 am
- NII HLDGS-CL B (NIHD) - Profit Tracks - Zacks 02.17.12 | 01:02 am
- The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company - Press Releases - Zacks 02.06.12 | 09:02 am
- The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases - Zacks 02.01.12 | 09:02 am





